Advances in the understanding of the molecular basis of cancer have led to the identification of key pathways and molecules involved in tumor initiation and progression. Translating this innovative science into the next generation of therapeutic agents remains as one of the major hurdles in making meaningful improvements in cancer treatment. While the multi-factorial nature of cancer drug discovery makes the endeavor extremely challenging, real progress is being made. This symposium will provide the first disclosure of the chemistry and biology of promising new small molecules that are nearing or have recently advanced into clinical trials.
Drug Development Track-Special Session 2: New Drugs on the Horizon

Discovery and characterization of E6201: A potent natural product-inspired synthetic MEK1 inhibitor; Kenichi Nomoto. Eisai Research Institute, Andover, MA

MCS110: a monoclonal antibody with potent neutralizing activity against macrophage colony-stimulating factor for the treatment of tumor-induced osteolysis; Nancy K. Pryer. Novartis Institutes for BioMedical Research, Emeryville, CA

Targeting the replication checkpoint with a potent and selective CHK1 inhibitor; David A. Parry. Schering-Plough Biopharma, Palo Alto, CA,